Cat. # AG-CR1-3705
| Product Details | |
|---|---|
| Synonyms | NSA; (2E)-N-[4-[[(3-Methoxy-2-pyrazinyl)amino]sulfonyl]phenyl]-3-(5-nitro-2-thienyl)-2-propenamide |
| Product Type | Chemical |
| Properties | |
| Formula | C18H15N5O6S2 |
| MW | 461.5 |
| CAS | 1360614-48-7 |
| Purity Chemicals | ≥95% |
| Appearance | Off-white to yellow solid. |
| Solubility | Soluble in DMSO (20mg/ml) or DMF (20mg/ml). Insoluble in water. |
| InChi Key | FNPPHVLYVGMZMZ-XBXARRHUSA-N |
| Smiles | O=C(/C=C/C1=CC=C([N+]([O-])=O)S1)NC2=CC=C(S(NC3=C(OC)N=CC=N3)(=O)=O)C=C2 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Necrosulfonamide
- Inhibitor of necroptosis, by blocking mixed lineage kinase domain-like protein (MLKL), a key substrate of receptor-interacting serine-threonine kinase 3 (RIP3). Shown to prevent the MLKL-RIP1-RIP3 necrosome complex from interacting with downstream necrosis effectors.
- Potent inhibitor of gasdermin D that works well for mice studies. It binds directly to gasdermin D and inhibits the oligomerization of the N-terminus and therefore the pore formation and pyroptosis.
- Displayed neuroprotective effects after ischemic brain injury, prevented cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells and rescued cells from TLR3 ligand-induced death.
Product References
Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase: L. Sun, et al.; Cell 148, 213 (2012)
Necrosulfonamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein: D. Liao, et al. Med. Chem. Commun. 5, 333 (2014)
The degradation of mixed linage kinase domain-like protein promotes neuroprotection after ischemic brain injury: Y. Zhou, et al.; Oncotarget 8, 68393 (2017)
CHAC1 degradation of glutathione enhances cysteine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-elF2α-ATF4 pathway: M.S. Chen, et al.; Oncotarget 8, 114588 (2017)
Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis: D. Nakazawa, et al.; Cell Death Discov. 5,(2018)
Necrosulfonamide attenuates spinal cord injury via necroptosis inhibition: Y. Wang, et al.; World Neurosurg. 114, e1186 (2018)
Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis: J.K. Rathkey, et al.; Sci. Immunol. 3, eaat2738 (2018)
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation: D. Cuchet-Lourenco, et al.; Science 361, 810 (2018)